Hemostemix Inc. (FRA:2VF0)

Market Cap	11.51M -48.4%
Revenue (ttm)	n/a
Net Income	-2.08M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0435
Previous Close	0.0435
Day's Range	0.0435 - 0.0435
52-Week Range	0.0300 - 0.3580
Beta	n/a
RSI	48.92
Earnings Date	Apr 29, 2026

About Hemostemix

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate ...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Thomas Smeenk
• Country: Canada
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2VF0

Financial Performance

Financial numbers in CAD